ANTICOAGULATION IN COVID 19 (The REMAP-CAP, ACTIV-4a, | UPDATES IN MEDICINE
ANTICOAGULATION IN COVID 19
(The REMAP-CAP, ACTIV-4a, and ATTACC Investigators)
Anticoagulation in Critically Ill Patients with Covid-19
In a randomized trial, patients with severe Covid-19 were assigned to receive either therapeutic-dose anticoagulation or usual-care pharmacologic thromboprophylaxis. At 21 days, therapeutic-dose anticoagulation did not improve hospital survival or the number of days free of cardiovascular or respiratory organ support.
Anticoagulation in Moderate Covid-19
In a randomized trial, patients with moderately severe Covid-19 were assigned to receive either therapeutic-dose anticoagulation or usual-care thromboprophylaxis. At 21 days, therapeutic-dose anticoagulation resulted in a higher probability of survival until hospital discharge without organ support.
● Join @Updates_in_Medicine
● Click the links below to read full articles
